Physician profile
Leia Rispoli
NPI 1679993406
$34,943.71
in general payments reported to CMS, 2019-2025
30 companies · $13K in 2025
The $13K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,608 · 2020: $2,724 · 2021: $2,537 · 2022: $1,006 · 2023: $3,646 · 2024: $6,197 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $9,788 · Food and Beverage: $9,376 · Travel and Lodging: $3,905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $9,787.50 |
| Food and Beverage | $9,376.29 |
| Travel and Lodging | $3,904.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $16,209.66 | 2021-2025 | Nalu Neurostimulation System |
| Boston Scientific Corporation | $7,311.96 | 2019-2025 | Wavewriter Alpha Prime 16, General - Pain Management, Intracept |
| Medtronic USA, INC. | $3,272.74 | 2019-2020 | |
| Abbott Laboratories | $2,295.00 | 2019-2025 | Proclaim, Eterna |
| Medtronic, INC. | $1,116.77 | 2021-2025 | Intellis Adaptivestim |
| Merz Pharmaceuticals, LLC | $1,094.84 | 2021-2025 | Xeomin |
| Nevro Corp. | $1,060.26 | 2019-2024 | Senza |
| Biotronik Nro, INC. | $542.21 | 2023-2024 | Prospera, Biotronik |
| Curonix LLC | $467.49 | 2024-2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Brixton Biosciences, INC. | $158.03 | 2025 | Neural Ice |
| Globus Medical, INC. | $142.85 | 2025 | Senza |
| Allergan, INC. | $126.88 | 2019 | |
| Vertiflex, INC. | $121.86 | 2019 | |
| Mml US, INC. | $116.93 | 2023-2025 | Reactiv8 |
| Saluda Medical Americas, INC. | $114.12 | 2024-2025 | Evoke |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $112.48 | 2019-2023 | Intracept |
| Stratus Medical, LLC | $112.24 | 2020-2023 | Nimbus |
| Vertex Pharmaceuticals Incorporated | $106.31 | 2024-2025 | |
| Spr Therapeutics, INC | $66.05 | 2021 | |
| Merz North America, INC. | $64.51 | 2019-2020 | |
| Abbvie INC. | $58.01 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $57.10 | 2025 | Dysport |
| Pfizer INC. | $44.84 | 2019-2020 | |
| Lundbeck LLC | $34.56 | 2020-2021 | |
| Vertos Medical, INC. | $32.93 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $25.73 | 2023 | Iovera, Zilretta |
| Ibsa Pharma INC. | $21.27 | 2020 | |
| Depuy Synthes Sales INC. | $20.43 | 2025 | Monovisc |
| Lilly USA, LLC | $20.17 | 2020 | |
| Collegium Pharmaceutical, INC. | $15.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leia Rispoli listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.